Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Functionally high-risk myeloma has higher rates of EMD and progression w/ in 12 mos of transplant; FHRMM pts receiving CAR T as late LOT had inferior survival vs. non-FHR dz driven by active EMD and high dz burden at CAR T.”
Title: Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma
Authors: Hamza Hashmi, Tara Sebastian, Sridevi Rajeeve, Tasmin Farzana, Ross S. Firestone, Eric M. Jurgens, Kevin C. Miller, Francesco Maura, Alexander M. Lesokhin, Carlyn R. Tan, Gunjan L. Shah, Neha Korde, Heather J. Landau, Maximillian Merz, Michael Scordo, Hani Hassoun, Kylee H. Maclachlan, Urvi A. Shah, Malin L. Hultcrantz, Andriy Derkach, David Nemirovsky, Sergio Giralt, Sham Mailankody, Saad Z. Usmani
You can read the Full Article in Blood Cancer Journal.
You can find other articles featuring Robert Orlowski on OncoDaily.
